Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | À§½Ã¸®½ºÆ®
EnglishJapaness Traditional Chinese Simplified Chinese
Ȩ > ±Û·Î¹ú ÆÄÆ®³Ê > La Merie Publishing
Ä«Å×°í¸®·Î ã±â
Áö¿ªº°

La Merie Publishing

½ºÆäÀÎ ¹Ù¸£¼¿·Î³ª¿¡ º»»ç¸¦ µÐ La Merie´Â ¹ÙÀÌ¿À Å×Å©³î·¯Áö ¹× Á¦¾à »ê¾÷¿¡ ´ëÇÑ ¸®¼­Ä¡¸¦ Àü¹®À¸·Î Çϰí ÀÖ½À´Ï´Ù.

»ó¼¼ ºÐ·ù
Á¦¸ñ °Ë»ö
1 - 25 ¸®ºä (Àüü£º 27 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
302689
¹ßÇàÁ¤º¸
¿¬°£±¸µ¶
ÆäÀÌÁö Á¤º¸
 
°¡°Ý
US $ 7,400 -> £Ü 8,883,000
RNA-Targeted Small Molecules 2019: A Landscape Analysis of Companies, Technologies, Targets, Investors and Partners from an Industry Perspective
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
911032
¹ßÇà
2019³â 09¿ù
ÆäÀÌÁö Á¤º¸
223 Pages
°¡°Ý
US $ 2,350 -> £Ü 2,821,000
¿­¶÷¼­ºñ½º
Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
890224
¹ßÇà
2019³â 06¿ù
ÆäÀÌÁö Á¤º¸
125 Pages
°¡°Ý
US $ 900 -> £Ü 1,080,000
¿­¶÷¼­ºñ½º
2 Reports Bundle - Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases plus T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
890416
¹ßÇà
2019³â 06¿ù
ÆäÀÌÁö Á¤º¸
 
°¡°Ý
US $ 2,840 -> £Ü 3,409,000
¿­¶÷¼­ºñ½º
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
868394
¹ßÇà
2019³â 06¿ù
ÆäÀÌÁö Á¤º¸
463 Pages
°¡°Ý
US $ 2,700 -> £Ü 3,241,000
¿­¶÷¼­ºñ½º
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
408112
¹ßÇà
2018³â 07¿ù
ÆäÀÌÁö Á¤º¸
455 Pages
°¡°Ý
US $ 1,690 -> £Ü 2,028,000
¿­¶÷¼­ºñ½º
6 Reports Bundle: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
651129
¹ßÇà
2018³â 06¿ù
ÆäÀÌÁö Á¤º¸
 
°¡°Ý
US $ 955 -> £Ü 1,146,000
¿­¶÷¼­ºñ½º
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
651128
¹ßÇà
2018³â 05¿ù
ÆäÀÌÁö Á¤º¸
 
°¡°Ý
US $ 3,505 -> £Ü 4,207,000
¿­¶÷¼­ºñ½º
TCR Engineered T-Cell Therapy 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
642119
¹ßÇà
2018³â 05¿ù
ÆäÀÌÁö Á¤º¸
294 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,001,000
¿­¶÷¼­ºñ½º
Intracellular Targets Made Druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: An Industry Analysis of Technologies, Stakeholders, Deals & Trends
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
600758
¹ßÇà
2018³â 01¿ù
ÆäÀÌÁö Á¤º¸
251 Pages
°¡°Ý
US $ 2,800 -> £Ü 3,361,000
¿­¶÷¼­ºñ½º
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
358307
¹ßÇà
2017³â 11¿ù
ÆäÀÌÁö Á¤º¸
58 Pages
°¡°Ý
US $ 525 -> £Ü 630,000
¿­¶÷¼­ºñ½º
2 Reports Bundle: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
579795
¹ßÇà
2017³â 10¿ù
ÆäÀÌÁö Á¤º¸
 
°¡°Ý
US $ 3,600 -> £Ü 4,321,000
¿­¶÷¼­ºñ½º
mRNA Vaccines & Therapeutics 2017: An Industry Analysis of Technologies, Pipelines, Stakeholders and Deals
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
518829
¹ßÇà
2017³â 06¿ù
ÆäÀÌÁö Á¤º¸
260 Pages
°¡°Ý
US $ 2,520 -> £Ü 3,025,000
¿­¶÷¼­ºñ½º
The Oncolytic Virus Landscape 2017: An Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
425869
¹ßÇà
2017³â 01¿ù
ÆäÀÌÁö Á¤º¸
225 Pages
°¡°Ý
US $ 2,400 -> £Ü 2,881,000
¿­¶÷¼­ºñ½º
3 Reports Bundle: Hot Targets for Empowered Antibody and Cell Therapy Technologies
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
408113
¹ßÇà
2016³â 12¿ù
ÆäÀÌÁö Á¤º¸
202 Pages
°¡°Ý
US $ 1,254 -> £Ü 1,505,000
¿­¶÷¼­ºñ½º
2 Reports Bundle: T-Cell Immunotherapy by Bispecific Antibodies and CAR & TCR Engineered T-Cells (Two Reports released in 2016)
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
368816
¹ßÇà
2016³â 09¿ù
ÆäÀÌÁö Á¤º¸
 
°¡°Ý
US $ 3,400 -> £Ü 4,081,000
¿­¶÷¼­ºñ½º
CD123: A Paradigmatic Target for Immunotherapeutic Treatment Modalities
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
369010
¹ßÇà
2016³â 08¿ù
ÆäÀÌÁö Á¤º¸
83 Pages
°¡°Ý
US $ 800 -> £Ü 960,000
¿­¶÷¼­ºñ½º
B-Cell Maturation Antigen (BCMA): Hot Target for Emerging Treatment Modalities
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
369011
¹ßÇà
2016³â 08¿ù
ÆäÀÌÁö Á¤º¸
39 Pages
°¡°Ý
US $ 570 -> £Ü 684,000
¿­¶÷¼­ºñ½º
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of Technologies Opens Business Opportunities Beyond CD19 CARTs
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
366651
¹ßÇà
2016³â 08¿ù
ÆäÀÌÁö Á¤º¸
388 Pages
°¡°Ý
US $ 2,750 -> £Ü 3,301,000
¿­¶÷¼­ºñ½º
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
327820
¹ßÇà
2016³â 05¿ù
ÆäÀÌÁö Á¤º¸
462 Pages
°¡°Ý
US $ 1,450 -> £Ü 1,740,000
¿­¶÷¼­ºñ½º
T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
357780
¹ßÇà
2016³â 05¿ù
ÆäÀÌÁö Á¤º¸
230 Pages
°¡°Ý
US $ 2,400 -> £Ü 2,881,000
¿­¶÷¼­ºñ½º
RORgamma Modulators 2016: A Comparative Analysis of the Landscape of RORgamma Antagonists and Agonists
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
351304
¹ßÇà
2016³â 02¿ù
ÆäÀÌÁö Á¤º¸
88 Pages
°¡°Ý
US $ 1,050 -> £Ü 1,260,000
¿­¶÷¼­ºñ½º
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - A Pipeline, Technology, Stakeholder & Business Analysis
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
294276
¹ßÇà
2015³â 11¿ù
ÆäÀÌÁö Á¤º¸
470 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,001,000
¿­¶÷¼­ºñ½º
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
325905
¹ßÇà
2015³â 03¿ù
ÆäÀÌÁö Á¤º¸
201 Pages
°¡°Ý
US $ 2,630 -> £Ü 3,157,000
¿­¶÷¼­ºñ½º
Recombinant Coagulation Factors 2015: Maturation of Recombinant Clotting Factor Pipeline and Emergence of Gene Therapy and Alternative Procoagulants
¸®¼­Ä¡»ç
La Merie Publishing
»óǰÄÚµå
274454
¹ßÇà
2014³â 12¿ù
ÆäÀÌÁö Á¤º¸
210 Pages
°¡°Ý
US $ 2,795 -> £Ü 3,355,000
¿­¶÷¼­ºñ½º

»ó±â ÀÚ·á ÀÌ¿ÜÀÇ La Merie Publishing ÀÚ·áµµ ÁÖ¹® °¡´ÉÇÏ´Ï ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.